These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35908281)

  • 1. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes.
    Liu P; Ye M; Wu Y; Wu L; Lan K; Wu Z
    Cancer Med; 2023 Feb; 12(3):3201-3221. PubMed ID: 35908281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors.
    Yang X; Gao M; Xu R; Tao Y; Luo W; Wang B; Zhong W; He L; He Y
    Front Immunol; 2022; 13():969447. PubMed ID: 36032103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
    Li Z; Deng J; Sun J; Ma Y
    Front Immunol; 2020; 11():595207. PubMed ID: 33240283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).
    Wang Y; Yang S; Wan L; Ling W; Chen H; Wang J
    Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37326100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
    Oladejo M; Paulishak W; Wood L
    Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.
    Li H; Zhao A; Li M; Shi L; Han Q; Hou Z
    Front Immunol; 2022; 13():1046755. PubMed ID: 36569893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
    Liu Y; Chen Y; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.
    Metropulos AE; Munshi HG; Principe DR
    EBioMedicine; 2022 Dec; 86():104380. PubMed ID: 36455409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to immune checkpoint inhibitors.
    Nagasaki J; Ishino T; Togashi Y
    Cancer Sci; 2022 Oct; 113(10):3303-3312. PubMed ID: 35848888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
    Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
    Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.